Peripheral blood microRNA-15a is a potential biomarker for type 2 diabetes mellitus and pre-diabetes

Al‑Kafaji,Ghada; Al‑Mahroos,Ghazi; Alsayed,Nasreen  A.; Hasan,Zuheir  A.; Nawaz,Sadia; Bakhiet,Moiz

doi:10.3892/mmr.2015.4416

Peripheral blood microRNA-15a is a potential biomarker for type 2 diabetes mellitus and pre-diabetes

Authors:
- Ghada Al‑Kafaji
- Ghazi Al‑Mahroos
- Nasreen A. Alsayed
- Zuheir A. Hasan
- Sadia Nawaz
- Moiz Bakhiet
View Affiliations

Affiliations: Department of Molecular Medicine, College of Medicine and Medical Sciences, Arabian Gulf University, Manama 26671, Kingdom of Bahrain, Endocrinology Unit, Salmaniya Medical Complex, Salmaniya 13164, Kingdom of Bahrain, Gulf Diabetes Specialist Centre, Manama 21686, Kingdom of Bahrain, Department of Physiology, College of Medicine and Medical Sciences, Arabian Gulf University, Manama 26671, Kingdom of Bahrain
Published online on: October 1, 2015 https://doi.org/10.3892/mmr.2015.4416
Pages: 7485-7490

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs) are small non-coding RNAs that function as crucial regulators of gene expression. Recently, dysregulation of miRNA expression in the blood has been demonstrated to be associated with various diseases, including type 2 diabetes mellitus (T2D), suggesting a potential for their use as biomarkers of disease prognosis. The present study examined the expression levels of T2D‑associated miR‑15a in peripheral whole blood samples from patients with T2D, pre‑diabetes individuals exhibiting impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), as well as healthy control subjects, in order to investigate the potential of peripheral blood plasma miR‑15a as a biomarker for the prediction of T2D and pre‑diabetes. The present study included 24 patients with T2D, 22 IFG/IGT individuals and 24 healthy controls. The expression levels of miR‑15a were analyzed by reverse transcription-quantitative polymerase chain reaction. The results indicated that the peripheral blood miR‑15a expression levels were significantly decreased in patients with T2D and IFG/IGT individuals, compared with healthy control subjects (P<0.05). As determined by multivariate logistic regression analysis, lower miR‑15a expression was significantly associated with T2D (odds ratio [OR]; 95% confidence interval [CI]: 0.51; 0.16‑0.73, respectively; P<0.05) and pre‑diabetes (OR; 95% CI: 0.56; 0.23‑0.79, respectively; P<0.05). This association remained statistically significant following adjustment for age, body mass index and hypertension, as well as other biochemical indicators. Furthermore, a receiver operating characteristic analysis revealed that blood miR‑15a distinguished patients with T2D and IFG/IGT individuals from healthy controls (area under the curves; 95% CI: 0.864; 0.751‑0.977 and 95% CI: 0.852; 0.752‑0.953, respectively). These results demonstrated that peripheral blood miR‑15a expression levels were significantly lower in patients with T2D and IFG/IGT individuals, compared with healthy individuals. Thus, miR‑15a in peripheral whole blood may serve as a potential biomarker for T2D and pre-diabetes.

View Figures

View References

1	Wild S, Roglic G, Green A, Sicree R and King H: Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 27:1047–1053. 2004. View Article : Google Scholar : PubMed/NCBI
2	Alhyas L, McKay A and Majeed A: Prevalence of type 2 diabetes in the states of the Co-operation council for the Arab states of the Gulf: A systematic review. PLoS One. 7:e409482012. View Article : Google Scholar : PubMed/NCBI
3	Abdul-Ghani MA and DeFronzo RA: Pathophysiology of prediabetes. Curr Diab Rep. 9:193–199. 2009. View Article : Google Scholar : PubMed/NCBI
4	Cavaghan MK, Ehrmann DA and Polonsky KS: Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest. 106:329–333. 2000. View Article : Google Scholar : PubMed/NCBI
5	Harris MI, Klein R, Welborn TA and Knuiman MW: Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis. Diabetes Care. 15:815–825. 1992. View Article : Google Scholar : PubMed/NCBI
6	Thompson TJ, Engelgau MM, Hegazy M, Ali MA, Sous ES, Badran A and Herman WH: The Onset of NIDDM and its relationship to clinical diagnosis in Egyptian adults. Diabet Med. 13:337–340. 1996. View Article : Google Scholar : PubMed/NCBI
7	Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, et al: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 344:1343–1350. 2001. View Article : Google Scholar : PubMed/NCBI
8	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
9	Lynn FC, Skewes-Cox P, Kosaka Y, McManus MT, Harfe BD and German MS: MicroRNA expression is required for pancreatic islet cell genesis in the mouse. Diabetes. 56:2938–2945. 2007. View Article : Google Scholar : PubMed/NCBI
10	Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, Macdonald PE, Pfeffer S, Tuschl T, Rajewasky N, Rorsman P and Soffel M: A pancreatic islet-specific microRNA regulates insulin secretion. Nature. 432:226–230. 2004. View Article : Google Scholar : PubMed/NCBI
11	He A, Zhu L, Gupta N, Chang Y and Fang F: Overexpression of micro ribonucleic acid 29, highly up-regulated in diabetic rats, leads to insulin resistance in 3T3-L1 adipocytes. Mol Endocrinol. 21:2785–2794. 2007. View Article : Google Scholar : PubMed/NCBI
12	Plaisance V, Abderrahmani A, Perret-Menoud V, Jacquemin P, Lemaigre F and Regazzi R: MicroRNA-9 controls the expression of Granuphilin/Slp4 and the secretory response of insulin-producing cells. J Biol Chem. 281:26932–26942. 2006. View Article : Google Scholar : PubMed/NCBI
13	Tang X, Tang G and Ozcan S: Role of microRNAs in diabetes. Biochimic Biophysic Acta. 1779:697–701. 2008. View Article : Google Scholar
14	Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
15	Chen X, Liang H, Zhang J, Zen K and Zhang CY: Secreted microRNAs: A new form of intercellular communication. Trends Cell Biol. 22:125–132. 2012. View Article : Google Scholar : PubMed/NCBI
16	Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y and Ochiya T: Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem. 285:17442–17452. 2010. View Article : Google Scholar : PubMed/NCBI
17	Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
18	Yang X, Zeng Z, Hou Y, Yuan T, Gao C, Jia W, Yi X and Liu M: MicroRNA-92a as a potential biomarker in diagnosis of colorectal cancer: A systematic review and meta-analysis. PLoS One. 9:e887452014. View Article : Google Scholar : PubMed/NCBI
19	Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J, Qin YW and Jing Q: Circulating microRNA: A novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J. 31:659–666. 2010. View Article : Google Scholar : PubMed/NCBI
20	Fichtlscherer S, de Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, Weber M, Hamm CW, Röxe T, Müller-Ardogan M, et al: Circulating microRNAs in patients with coronary artery disease. Circ Res. 107:677–684. 2010. View Article : Google Scholar : PubMed/NCBI
21	Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, Mayr A, Weger S, Oberhollenzer F, Bonora E, et al: Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res. 107:810–817. 2010. View Article : Google Scholar : PubMed/NCBI
22	Roth P, Wischhusen J, Happold C, Chandran PA, Hofer S, Eisele G, Weller M and Keller A: A specific miRNA signature in the peripheral blood of glioblastoma patients. J Neurochem. 118:449–457. 2011. View Article : Google Scholar : PubMed/NCBI
23	Schrauder MG, Strick R, Schulz-Wendtland R, Strissel PL, Kahmann L, Loehberg CR, Lux MP, Jud SM, Hartmann A, Hein A, et al: Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS One. 7:e297702012. View Article : Google Scholar : PubMed/NCBI
24	Meder B, Keller A, Vogel B, Haas J, Sedaghat-Hamedani F, Kayvanpour E, Just S, Borries A, Rudloff J, Leidinger P, et al: MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction. Basic Res Cardiol. 106:13–23. 2011. View Article : Google Scholar
25	Keller A, Leidinger P, Bauer A, Elsharawy A, Haas J, Backes C, Wendschlag A, Giese N, Tjaden C, Ott K, et al: Toward the blood-borne miRNome of human diseases. Nat Methods. 8:841–843. 2011. View Article : Google Scholar : PubMed/NCBI
26	Alberti KG and Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 15:539–553. 1998. View Article : Google Scholar : PubMed/NCBI
27	Wong L, Lee K, Russell I and Chen C: Endogenous controls for realtime quantitation of miRNA using TaqMan^® MicroRNA assays. Macmillan Publishers Ltd; New York: 2007
28	Roggli E, Britan A, Gattesco S, Lin-Marq N, Abderrahmani A, Meda P and Regazzi1 R: Involvement of microRNAs in the cytotoxic effects exerted by proinflammatory cytokines on pancreatic beta-cells. Diabetes. 59:978–986. 2010. View Article : Google Scholar : PubMed/NCBI
29	Poy MN, Hausser J, Trajkovski M, Braun M, Collins S, Rorsman P, Zavolan M and Stoffel M: miR-375 maintains normal pancreatic alpha- and beta-cell mass. Proc Natl Acad Sci USA. 106:5813–5818. 2009. View Article : Google Scholar : PubMed/NCBI
30	Karolina DS, Armugam A, Tavintharan S, Wong MT, Lim SC, Sum CF and Jeyaseelan K: MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. PLoS One. 6:e228392011. View Article : Google Scholar : PubMed/NCBI
31	Bandi N, Zbinden S, Gugger M, Arnold M, Kocher V, Hasan L, Kappeler A, Brunnet T and Vassella E: miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res. 69:5553–5559. 2009. View Article : Google Scholar : PubMed/NCBI
32	Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, et al: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 102:13944–13949. 2005. View Article : Google Scholar : PubMed/NCBI
33	Sun LL, Jiang BG, Li WT, Zou JJ, Shi YQ and Liu ZM: MicroRNA-15a positively regulates insulin synthesis by inhibiting uncoupling protein-2 expression. Diabetes Res Clin Pract. 91:94–100. 2011. View Article : Google Scholar
34	Meigs JB, Muller DC, Nathan DM, Blake DR and Andres R: Baltimore Longitudinal Study of Aging: The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore longitudinal study of aging. Diabetes. 52:1475–1484. 2003. View Article : Google Scholar : PubMed/NCBI
35	Bock G, Dalla Man C, Campioni M, Chittilapilly E, Basu R, Toffolo G, Cobelli C and Rizza R: Pathogenesis of pre-diabetes: Mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes. 55:3536–3549. 2006. View Article : Google Scholar : PubMed/NCBI